Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats

Acta Pharmacologica Sinica

Volumn 24, Issue 3, 2003, Pages 256-262

  Zhong, Da Fang ^a   Li, Ke ^a   Xu, Jing Hua ^a   Du, Yue ^a   Zhang, Yi Fan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

9 nitro 20(S) camptothecin; Excretion; Pharmacokinetics; Rats

Indexed keywords

CAMPTOTHECIN; RUBITECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CELL DEATH; CONTROLLED STUDY; DATA ANALYSIS; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; DRUG DETERMINATION; DRUG EXCRETION; NONHUMAN; PLANT LEAF; RAT; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BILE; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; FECES; INJECTIONS, INTRAVENOUS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; URINE;

EID: 0037336122     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Underbreg WJM, Goosen RMJ, Smith BR, Beijnen JH. Equilibrium kinetics of the new experimental antitumour compound SK&F 104684-A in aqueous solution. J Pharmacol Biomed Anal 1990; 8: 681-3.
2. Staubus AE, Rutherford M, Snuffer P, Feller D. Kinetics of ring opening of camptothecin analogs and topotecan in plasma and whole blood. Proc Am Assoc Cancer Res 1992; 33:531.
3. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9: 36-44.
4. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agent. Ann NY Acad Sci 1996; 803: 224-30.
5. Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999; 10: 375-83.
6. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20 (S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 1994; 54: 3096-100.
7. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 1991; 51: 3052-5.
8. Verschraegen CF, Gilbert BE, Huaringa AJ, Newman R, Harris N, Leyva FJ, et al. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann N Y Acad Sci 2000; 922: 352-4.
9. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999; 44: 187-92.
10. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Kleinerman E, Gilbert BE. Anticancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans Am Clin Climatol Assoc 2000; 111: 135-45.
11. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999; 44: 177-86.
12. Chow DS, Gong L, Wolfe MD, Giovanella BC. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Ann NY Acad Sci 2000; 922: 164-74.